• Product NameAvasimibe
• Brief DescriptionInhibitors
• Purification98.91%
• Biological ActivityAvasimibe inhibits ACAT with IC50 of 3.3 μM, also inhibits human P450 isoenzymes CYP2C9, CYP1A2 and CYP2C19 with IC50 of 2.9 μM, 13.9 μM and 26.5 μM, respectively.
• Target NameACAT inhibitor; P450 inhibitor
• CAS No. 166518-60-1
• Calculated MW 501.72
• Formulation C29H43NO4S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Metabolism system
  SMILES:CC(C)C1=CC(C(C)C)=C(CC(=O)NS(=O)(=O)OC2=C(C=CC=C2C(C)C)C(C)C)C(=C1)C(C)C
  Pathways:Metabolism; Others
  Receptor:ACAT; CYP1A2; CYP2C19; CYP2C9
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 8 mg/mL (15.94 mM); DMSO: 100 mg/mL (199.31 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Lee HT, et al. J Med Chem, 1996, 39(26), 5031-5034.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting